ZTS SEC Filings

Zoetis Inc. reported solid financial results for the fiscal year ended December 31, 2025, with total revenue reaching $9.47 billion, a 2% increase year-over-year, driven by a 3% operational revenue growth. This growth was primarily attributed to price increases and contributions from key product franchises, partially offset by the impact of a divestiture. Net income grew 8% to $2.67 billion. The company continues to demonstrate strength in both its U.S. and International segments, with companion animal products representing a significant 70% of total revenue. Key product lines like Simparica/Simparica Trio and Apoquel/Apoquel Chewable remain strong contributors, accounting for a substantial portion of overall revenue. Zoetis also continues to invest in research and development, with expenses totaling $698 million, focusing on both new product development and lifecycle innovation. The company's balance sheet remains robust, with total assets growing to $15.47 billion. Zoetis actively manages its capital structure, including a significant share repurchase program of up to $6 billion, demonstrating a commitment to returning value to shareholders. The company's financial health is supported by a strong credit facility and diverse revenue streams across multiple species and product categories. Looking ahead, Zoetis is focused on its strategic pillars of innovation, customer experience, digital solutions, talent development, sustainability, and operational excellence to drive continued growth in the dynamic animal health market.

Zoetis Inc. (ZTS) has filed an 8-K report on February 12, 2026, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2025. The filing also includes the company's financial guidance for the upcoming full year 2026. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial performance metrics and future outlook. While specific figures are not detailed within the 8-K text itself, the furnished press release is the key document for understanding Zoetis' performance in 2025, including revenue, profitability, and key growth drivers. Furthermore, the guidance provided for 2026 will be crucial for assessing the company's strategic direction and potential for continued growth in the animal health sector.

Zoetis Inc. (ZTS) has filed a Current Report (8-K) on February 5, 2026, primarily announcing its second-quarter 2026 dividend declaration. The company has declared a dividend of $0.53 per share, which is a positive signal to investors regarding the company's financial health and commitment to returning capital to shareholders. This dividend payment is scheduled for June 2, 2026, with a record date of April 20, 2026, providing clear timelines for eligible shareholders.

Zoetis Inc. has successfully completed a private offering of $2.0 billion in aggregate principal amount of 0.25% Convertible Senior Notes due 2029. The net proceeds, estimated at approximately $1.97 billion after expenses, are earmarked for a significant share repurchase program, with a substantial portion intended for additional repurchases by the first quarter of 2026, supplementing its existing $6 billion repurchase authorization. The company also entered into capped call transactions to mitigate potential dilution from the convertible notes. Additionally, Zoetis obtained a waiver from its lenders under its revolving credit facility to explicitly permit early conversions of these new notes. This strategic financing move, coupled with the share repurchase initiative, signals the company's intent to return capital to shareholders while maintaining financial flexibility. Investors should monitor the execution of the share buyback program and the impact of these new notes on the company's capital structure and future earnings per share.

Zoetis Inc. (ZTS) has announced its first-quarter 2026 dividend, demonstrating a consistent commitment to returning capital to shareholders. The company declared a dividend of $0.53 per share, payable on March 3, 2026, to shareholders of record as of January 20, 2026. This regular dividend payment is a key indicator of the company's financial stability and its confidence in sustained profitability. While this filing is primarily a Regulation FD disclosure regarding the dividend, it underscores Zoetis' ongoing capital allocation strategy. Investors should view this as a positive signal of the company's financial health and its ability to generate consistent cash flows to support shareholder returns. Further analysis of Zoetis' broader financial performance, strategic initiatives, and market position would be necessary for a complete investment assessment.

Zoetis Inc. (ZTS) has filed a Current Report on Form 8-K to announce an upcoming Innovation Webcast scheduled for December 2, 2025, at 8:30 a.m. ET. The primary purpose of this filing is to provide investors with advance notice of the event and to make available the presentation materials that will be used during the webcast. This webcast is expected to focus on the company's latest innovations, which could include new product pipelines, research and development advancements, or strategic initiatives aimed at driving future growth in the animal health sector. Investors should pay close attention to this webcast as it represents an opportunity to gain insights into Zoetis's forward-looking strategy and its potential impact on future financial performance. The attached presentation, incorporated by reference, will likely detail key areas of innovation, potential market opportunities, and the company's competitive positioning. Understanding these elements is crucial for assessing Zoetis's long-term value proposition and its ability to maintain its leadership in the animal health industry.

Zoetis Inc. (ZTS) has filed an 8-K report on November 4, 2025, to disclose its financial results for the third quarter of 2025 and provide updated guidance for the full year 2025. While the full details of the results and guidance are contained within the furnished press release (Exhibit 99.1), this filing signals an important update for investors regarding the company's recent performance and future outlook. Investors should carefully review the press release for specific revenue figures, profitability metrics, and any changes to the previously issued full-year financial projections. The key takeaway for investors is to understand the performance drivers behind the Q3 results and how these are expected to impact the company's ability to meet its revised full-year targets. This includes assessing any commentary on market conditions, product demand, and strategic initiatives that may have influenced the quarter's outcomes. The provided guidance will be crucial in evaluating Zoetis's trajectory for the remainder of 2025 and its potential to deliver shareholder value.

Zoetis Inc. reported solid financial results for the nine months ended September 30, 2025, with revenue increasing by 2% to $7.08 billion and net income attributable to Zoetis Inc. growing by 9% to $2.07 billion. This growth was driven by a combination of price increases and volume growth in key franchises, partially offset by the impact of a divestiture. The company demonstrated improved cost management, with Cost of Sales as a percentage of revenue decreasing from 29.0% to 27.6% year-over-year for the nine-month period. Key financial highlights include a robust increase in diluted Earnings Per Share (EPS) by 11% to $4.65 for the nine-month period. The company also managed its balance sheet effectively, with cash and cash equivalents increasing to $2.08 billion and a strong working capital position. Zoetis maintained compliance with its debt covenants and has a significant authorization remaining for its share repurchase program, indicating a continued focus on returning value to shareholders.

Zoetis Inc. (ZTS) announced a strategic addition to its Board of Directors, appointing Stephanie Tilenius as a new member, effective December 1, 2025. This appointment will increase the Board's size from twelve to thirteen directors. Ms. Tilenius brings significant experience, which is expected to contribute to the company's strategic direction and governance. The company has also confirmed that Ms. Tilenius's appointment is not contingent on any third-party arrangements and that there have been no reportable related-party transactions. She will be compensated according to the company's standard non-employee director compensation program, and Zoetis will enter into its standard indemnification agreement with her. The announcement was made via a press release on October 28, 2025.

Zoetis Inc. (ZTS) has filed a current report (8-K) on October 9, 2025, primarily announcing the declaration of its fourth-quarter 2025 dividend. This dividend amounts to $0.50 per share, providing a direct return of capital to shareholders. The payment date is scheduled for December 2, 2025, with a record date of October 31, 2025. This announcement is a routine event for investors seeking income from their ZTS holdings. While this filing is limited in scope, focusing on the dividend declaration, it's important for shareholders to note the ex-dividend and payment dates to ensure they are holders of record in time to receive the payout. The company has also provided the standard disclaimer that the information is not deemed 'filed' for regulatory purposes unless specifically incorporated into other filings.

Zoetis Inc. (ZTS) has announced the execution of a new $1.25 billion senior unsecured revolving credit facility, effective August 27, 2025. This facility, which matures in five years, replaces the company's previous credit agreement and provides enhanced financial flexibility with an option to increase the total commitment to $1.75 billion. The new credit line offers competitive borrowing terms, with interest rates tied to SOFR or a base rate plus an applicable margin, and includes a facility fee on commitments. The agreement's covenants focus on maintaining a maximum total leverage ratio and include standard restrictions on asset sales, mergers, and incurring priority debt, which are typical for a company of Zoetis's financial standing. The termination of the prior credit agreement, originally set to expire in December 2027, signifies a strategic move by Zoetis to optimize its capital structure and ensure access to liquidity on favorable terms. This proactive refinancing demonstrates the company's commitment to maintaining a strong balance sheet and its ability to secure robust financing arrangements to support its ongoing operations and strategic growth initiatives. Investors can view this as a positive development, indicating sound financial management and a focus on operational efficiency.

Zoetis Inc. (ZTS) has filed an 8-K report detailing a significant debt financing event. On August 11, 2025, the company entered into an Underwriting Agreement to issue and sell $850 million of 4.150% Senior Notes due 2028 and $1 billion of 5.000% Senior Notes due 2035, totaling $1.85 billion in aggregate principal amount. These notes were issued under an existing indenture supplemented by a seventh supplemental indenture, with Deutsche Bank Trust Company Americas acting as the trustee. The offering was registered on Form S-3. This transaction represents a substantial capital raise for Zoetis, likely intended to fund ongoing operations, strategic initiatives, or potential acquisitions. Investors should note the specific interest rates and maturity dates for each tranche of notes, which will impact the company's future interest expense and debt repayment obligations. The filing provides detailed exhibits regarding the underwriting agreement and the indentures governing these new senior notes.

Zoetis Inc. (ZTS) filed an 8-K on August 5, 2025, to report its financial results for the second quarter of 2025 and provide guidance for the full year 2025. The key investor takeaway from this filing is the announcement of these financial outcomes and forward-looking statements, which are detailed in the accompanying press release furnished as Exhibit 99.1. While the 8-K itself is a formal disclosure mechanism, the substantive financial data and management commentary are contained within the press release. Investors should refer to Exhibit 99.1 for specifics on revenue, profitability, segment performance, and updated financial projections for the remainder of 2025. This information is crucial for assessing the company's current performance and its future outlook.

Zoetis Inc. reported solid financial results for the second quarter and first half of 2025. Revenue increased by 4% to $2.46 billion for the quarter and 3% to $4.68 billion for the first half, demonstrating continued growth driven by price increases and strong performance in key franchises, particularly in companion animal products. Diluted earnings per share also saw a significant increase, rising to $1.61 for the quarter and $3.02 for the half, up from $1.37 and $2.68 respectively in the prior year periods. This growth reflects effective cost management, including a reduction in the cost of sales as a percentage of revenue, and a strategic focus on higher-margin products. The company continues to navigate a dynamic global environment, with operational revenue growth outpacing reported growth due to unfavorable foreign exchange rates. Despite these headwinds, Zoetis maintains a strong financial position, evidenced by healthy operating cash flow and a robust balance sheet. The company also highlighted ongoing investments in research and development to fuel future innovation and maintain its leadership position in the animal health sector. Shareholder returns remain a priority, with continued share repurchases under its authorized program.

Zoetis Inc. (ZTS) filed an 8-K on May 21, 2025, detailing the outcomes of its 2025 Annual Meeting of Shareholders held on May 20, 2025. The key event for investors from a governance perspective is the retirement of Mr. Robert Scully from the Board of Directors and the subsequent election of Dr. Mark Stetter to fill the vacancy. This change in board composition, effective May 21, 2025, is a routine board refreshment in line with the company's retirement policy. Furthermore, the filing provides critical voting results from the Annual Meeting. Shareholders overwhelmingly approved the election of all twelve director nominees, including the newly appointed Dr. Stetter, and ratified the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2025. The compensation program for named executive officers also received shareholder approval on a non-binding advisory basis, indicating general alignment between management's pay practices and investor sentiment. However, a shareholder proposal seeking improvements to special shareholder meeting rights was not approved.

Zoetis Inc. (ZTS) has filed an 8-K report on May 21, 2025, primarily disclosing a regular quarterly dividend declaration. The company announced a dividend of $0.500 per share for the third quarter of 2025. This action signals continued confidence in the company's financial health and its commitment to returning value to shareholders. Investors should note the payment date of September 3, 2025, and the record date of July 18, 2025, for eligibility. While this filing does not contain new financial performance data or strategic shifts, the consistent dividend payout is a positive indicator for income-focused investors. The declaration aligns with Zoetis's established practice of providing regular returns, suggesting stable operational performance and a solid cash flow generation capability. Investors seeking income from their ZTS holdings can anticipate this distribution as per the announced schedule.

Zoetis Inc. (ZTS) has filed an 8-K report on May 6, 2025, detailing its first-quarter 2025 financial results and providing its full-year 2025 guidance. This report, which includes a press release, serves to inform investors about the company's recent performance and future outlook. While the specific financial figures and guidance details are contained within the furnished press release (Exhibit 99.1), the filing signals Zoetis' ongoing operational activities and strategic planning. Investors should review the attached press release for a comprehensive understanding of the reported results, including key metrics such as revenue, profitability, and any notable segment performances, as well as the company's forward-looking projections for the remainder of fiscal year 2025.

Zoetis Inc. reported revenue of $2,220 million for the first quarter of 2025, a slight increase of 1% compared to $2,190 million in the prior year period. On an operational basis, excluding foreign exchange impacts, revenue grew by 5%. This growth was driven by a 4% increase in pricing and a 4% volume increase from key franchises, partially offset by a 4% decrease related to the divestiture of its medicated feed additive (MFA) portfolio. Net income attributable to Zoetis Inc. rose by 5% to $631 million, or $1.41 per diluted share, up from $599 million, or $1.31 per diluted share, in the first quarter of 2024. The company's effective tax rate increased to 22.1% from 19.8%, impacting profitability. The company experienced a notable shift in its revenue mix, with companion animal products showing robust growth (up 7% overall, 9% operationally) while livestock products saw a decline (down 10% overall, 5% operationally). This is largely attributable to the MFA divestiture impacting livestock sales. Geographically, the U.S. segment saw a 2% revenue increase driven by companion animal products, while the International segment's revenue was flat overall but grew 7% operationally, with both companion animal and livestock segments contributing positively on an operational basis. The company continued its share repurchase program, buying back $443 million worth of stock in the quarter.

Zoetis Inc. reported strong financial performance for the fiscal year ended December 31, 2024, with total revenue reaching $9.26 billion, an increase of 8% year-over-year. This growth was driven by an 11% operational revenue increase, fueled by price adjustments (6%) and volume growth from new products and key dermatology products (3% and 2% respectively). The company's U.S. segment showed robust growth of 11%, while the International segment experienced a 5% increase in revenue, partially impacted by unfavorable foreign exchange. Companion animal products continue to be the primary revenue driver, accounting for approximately 68% of total revenue, with livestock products making up 31%. The company's top-selling products, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, remain significant contributors to overall revenue. Zoetis demonstrated effective cost management, with cost of sales as a percentage of revenue decreasing to 29.4% due to price increases, favorable product mix, and lower inventory and freight costs. Selling, general, and administrative expenses also saw an 8% increase, largely attributed to investments in compensation, selling, and promotional activities. Research and development expenses grew by 12%, reflecting continued investment in innovation and portfolio progression. The company also completed the divestiture of its medicated feed additive product portfolio in October 2024, which will impact future revenue streams. Zoetis remains committed to returning value to shareholders, evidenced by its completed $3.5 billion share repurchase program and a new $6 billion authorization, underscoring confidence in its future performance.

Zoetis Inc. (ZTS) has filed a Current Report on Form 8-K on February 13, 2025, primarily to furnish its earnings press release for the fourth quarter and full year 2024. This release also provides the company's financial outlook and guidance for the full year 2025. Investors should refer to the furnished press release (Exhibit 99.1) for specific details on financial performance and future expectations. The filing indicates that the information shared is for informational purposes and is not deemed "filed" under Section 18 of the Exchange Act, meaning it doesn't carry the same regulatory implications as a formally filed document. However, it serves as a crucial update for stakeholders regarding the company's operational results and strategic projections.

Zoetis Inc. (ZTS) has filed an 8-K report on February 6, 2025, primarily disclosing the declaration of its second quarter 2025 dividend. Investors will note that the company has declared a dividend of $0.500 per share, payable on June 3, 2025, to shareholders of record as of April 21, 2025. This announcement, made via a press release on February 6, 2025, provides a clear signal of the company's ongoing commitment to returning capital to its shareholders.

Zoetis Inc. (ZTS) has filed an 8-K report indicating that its executive management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The primary purpose of this filing is to furnish the presentation materials, which are provided as Exhibit 99.1. This event offers investors an opportunity to hear directly from company leadership regarding Zoetis's strategic direction, business updates, and potentially future outlook within the animal health sector. While this filing does not contain new financial results or material business changes, the presentation materials are crucial for understanding management's current messaging and focus areas. Investors should pay close attention to any forward-looking statements, discussions on market trends, product pipeline updates, and competitive landscape insights that may be shared during the conference. The information provided is for informational purposes and is not deemed "filed" for regulatory purposes unless specifically incorporated into a future filing.

Zoetis Inc. (ZTS) announced on December 12, 2024, the declaration of its first-quarter 2025 dividend. This regular dividend payment demonstrates the company's continued commitment to returning capital to shareholders, a sign of financial stability and confidence in ongoing operations. The dividend amount is set at $0.500 per share, with a payment date of March 4, 2025, for shareholders of record as of January 21, 2025. While this filing is primarily for the disclosure of the dividend, it's important for investors to note that this information is furnished under Regulation FD and is not considered "filed" for the purposes of the Securities Exchange Act of 1934. This means it doesn't automatically become part of future SEC filings unless specifically incorporated. Investors seeking further details on Zoetis's financial performance and strategic outlook should refer to other filings and communications from the company.

Zoetis Inc. (ZTS) has announced significant leadership changes through an 8-K filing on November 11, 2024, effective immediately and extending into early 2025. The most impactful change for investors is the departure of Wafaa Mamilli, Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, who will leave in early 2025 to pursue other opportunities. In response, Keith Sarbaugh has been promoted to Executive Vice President and Chief Digital & Technology Officer, tasked with leading the company's technology, digital, data, and analytics strategy. Further strategic realignments include the appointment of Jamie Brannan to a newly created role of Executive Vice President and Chief Commercial Officer, consolidating oversight of all global commercial markets. Ester Banque, Executive Vice President and President, U.S. Operations, will also depart in early 2025, with Jared Shriver promoted to President, U.S. Operations, reporting to Mr. Brannan. These changes suggest a focus on strengthening commercial leadership and digital capabilities as the company navigates future growth.

Zoetis Inc. reported strong financial results for the third quarter and the first nine months of 2024, demonstrating robust revenue growth driven by both price increases and product volume. For the three months ended September 30, 2024, total revenue increased by 11% year-over-year to $2.39 billion, with a 14% operational increase excluding foreign exchange impacts. Net income attributable to Zoetis Inc. grew by 14% to $682 million. For the nine-month period, revenue rose by 10% to $6.94 billion, and net income increased by 5% to $1.91 billion. The company's growth was propelled by its companion animal segment, particularly new products like Librela® and Solensia®, alongside strong performance in dermatology and parasiticides. While the company faces ongoing investments in R&D and SG&A, its cost management and operational efficiencies have contributed to sustained profitability. Zoetis also repurchased shares and declared dividends, indicating confidence in its financial health and commitment to returning value to shareholders.

Zoetis Inc. (ZTS) filed an 8-K on November 4, 2024, primarily to report its third-quarter 2024 financial results and provide updated guidance for the full year 2024. The key takeaway for investors is that the company has raised its full-year outlook, signaling confidence in its ongoing performance and growth trajectory. This positive development suggests that Zoetis is exceeding expectations and performing strongly across its business segments. Investors should focus on the details within the furnished press release (Exhibit 99.1) for specific metrics on revenue, profitability, and any commentary on key drivers or challenges. The upward revision in guidance is a significant indicator of management's positive outlook and is likely to be a primary focus for market participants assessing the company's future prospects.

Zoetis Inc. (ZTS) has filed an 8-K report on October 10, 2024, primarily announcing its fourth-quarter 2024 dividend. The Board of Directors declared a dividend of $0.432 per share, demonstrating a consistent commitment to returning capital to shareholders. This dividend is scheduled to be paid on December 3, 2024, to shareholders of record as of October 31, 2024. While this filing is routine and does not contain significant operational or financial updates, the dividend declaration is a key piece of information for income-focused investors. It signals continued financial stability and management's confidence in the company's ability to generate sufficient cash flow to support its dividend payout policy.

Zoetis Inc. (ZTS) reported strong top-line growth for the second quarter and first half of 2024, with total revenue increasing by 8% and 9% respectively, driven by a combination of price increases and volume growth in key product categories like dermatology and new products. Operationally, revenue growth was even more robust, up 11% for the quarter and 12% for the half-year, indicating underlying business strength despite unfavorable foreign exchange impacts. Profitability saw a decline in reported net income for the quarter, primarily due to higher restructuring and divestiture-related costs and other (income)/deductions—net, which included a significant loss on assets held for sale. However, excluding these items, adjusted net income and adjusted diluted EPS showed healthy year-over-year increases, demonstrating continued operational efficiency and profitability.

Zoetis Inc. (ZTS) has filed an 8-K report on August 6, 2024, announcing its second-quarter 2024 financial results and, more importantly for investors, raising its full-year 2024 guidance. While the specific details of the quarterly performance are not provided in this filing itself, the upward revision of future expectations suggests strong operational execution and a positive outlook for the animal health company. Investors should pay close attention to the accompanying press release (Exhibit 99.1) for the detailed financial metrics, including revenue, earnings per share, and segment performance, which underpin this raised guidance. The company's ability to exceed its previous forecasts highlights its continued strength in the market and potential for further growth.

Zoetis Inc. (ZTS) announced a significant new multi-year share repurchase program, authorizing up to $6 billion in stock buybacks. This program reflects management's confidence in the company's financial health and its commitment to returning value to shareholders. The previous $3.5 billion program is nearing completion, underscoring a consistent approach to capital allocation. Investors should note that this program has no expiration date and is discretionary, meaning Zoetis is not obligated to repurchase any specific amount of stock. However, the substantial authorization signals a strong intention to reduce share count over time, potentially boosting earnings per share and providing a floor for the stock price.

Zoetis Inc. (ZTS) has filed an 8-K report detailing changes related to Heidi C. Chen's employment. Ms. Chen, previously a corporate officer, will continue with the company in a non-officer capacity until July 16, 2024, receiving her current salary and benefits. Following this date, she will transition to a non-employee consultant role until December 31, 2024. This transition includes specific compensation arrangements. Ms. Chen will receive a $350,000 consulting fee for her advisory services, contingent on her compliance with the agreement and execution of a release. She is also eligible for severance payments and benefits under the existing Zoetis Executive Severance Plan. Investors should note this is primarily an operational update regarding an executive transition, with no immediate impact on financial performance or strategic direction reported in this filing.

Zoetis Inc. (ZTS) filed an 8-K on May 22, 2024, detailing the outcomes of its Annual Meeting of Shareholders held on May 20, 2024. Key events include the retirement of Dr. Linda Rhodes from the Board of Directors and shareholder approval of an amendment to the Restated Certificate of Incorporation to provide exculpation for certain officers, which became effective on May 22, 2024. The Annual Meeting saw high shareholder participation, with nearly 90% of voting power represented. Investors will note that all twelve director nominees were re-elected for one-year terms, and the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 was ratified. The company's executive compensation program received advisory approval, indicating shareholder confidence in the current remuneration structure. However, a shareholder proposal concerning the director resignation policy was not approved.

Zoetis Inc. (ZTS) has filed an 8-K report on May 22, 2024, primarily disclosing its third quarter 2024 dividend. The company declared a dividend of $0.432 per share, which is scheduled to be paid on September 4, 2024, to shareholders of record as of July 18, 2024. This announcement provides a clear indication of the company's commitment to returning capital to its shareholders and offers a tangible return for investors holding the stock through the specified record date.

Zoetis Inc. reported strong financial results for the first quarter of 2024, with total revenue increasing by 10% to $2.19 billion compared to the same period in 2023. This growth was driven by a solid 12% increase on an operational basis, primarily attributed to price increases (7%), new product volume (4%), and key dermatology product volume (3%). Net income attributable to Zoetis Inc. rose by 9% to $599 million, with diluted earnings per share increasing from $1.19 to $1.31. The company's performance highlights the strength and resilience of the animal health market, with notable growth in companion animal products, particularly in the U.S. segment. The International segment also showed positive operational growth despite currency headwinds. Zoetis continues to invest in research and development to fuel future innovation and maintain its market leadership.

Zoetis Inc. (ZTS) filed an 8-K on May 2, 2024, primarily to report its first-quarter 2024 financial results and provide an updated full-year 2024 guidance. While the filing itself is brief, it indicates that the detailed financial performance and forward-looking statements are contained within the furnished press release (Exhibit 99.1). Investors should refer to the press release for specific figures regarding revenue, profitability, and any changes to the company's outlook for the remainder of 2024. This report serves as notification of the release of that information, which is crucial for assessing Zoetis' current operational standing and future prospects within the animal health sector.

Zoetis Inc. announced a significant leadership change, with Executive Vice President, General Counsel and Corporate Secretary, Heidi C. Chen, departing from her executive roles effective April 16, 2024. Ms. Chen will transition to an employee advisor role until July 16, 2024, and is expected to continue as a non-employee consultant thereafter. This departure marks a shift in the company's legal and corporate governance leadership. In response to Ms. Chen's departure, Roxanne Lagano, EVP, Chief Human Resources Officer and Global Operations, will assume the interim responsibilities of General Counsel and Corporate Secretary. Zoetis is actively searching for a permanent replacement, considering both internal and external candidates. Investors should note that Ms. Chen is eligible for severance benefits under the company's existing Executive Severance Plan and also qualifies for retirement-eligible benefits, as detailed in the company's recent Proxy Statement.

Zoetis Inc. (ZTS) announced a change to its Board of Directors via an 8-K filing on April 1, 2024. The company appointed Gavin D.K. Hattersley to the Board, increasing its size from twelve to thirteen members. Mr. Hattersley will also serve on the Board's Corporate Governance and Sustainability Committee. This appointment is effective April 1, 2024, and he will serve until his successor is appointed or qualified, or until his resignation or removal. Investors should note that Mr. Hattersley's appointment was not based on any arrangements with third parties, and there are no reportable related-party transactions. He will be compensated under the company's standard non-employee director compensation program. The filing also confirms the incorporation of a press release detailing this appointment as an exhibit.

Zoetis Inc. (ZTS) reported a solid performance in its 2023 10-K filing, demonstrating consistent revenue growth driven by both price increases and volume from new products. The company maintains a diversified portfolio across companion animal and livestock segments, with companion animal products representing a larger portion of revenue. Key therapeutic areas like parasiticides, dermatology, and vaccines continue to be strong contributors. Zoetis's strategic focus on innovation, customer experience, and digital solutions is evident in its R&D investments and product lifecycle management. The company also highlighted its commitment to sustainability and employee well-being, reflected in its human capital management initiatives and decreasing voluntary attrition rate. Despite some challenges like supply chain constraints and increasing competition, Zoetis's financial health remains robust, supported by strong operating cash flow and a healthy balance sheet, allowing for continued investment in growth and shareholder returns through share repurchases and dividends.

Zoetis Inc. (ZTS) has filed an 8-K report on February 13, 2024, announcing its fourth quarter and full-year 2023 financial results, along with initial guidance for the full year 2024. The key takeaway for investors is the release of this forward-looking financial information and the detailed performance metrics for the past fiscal year. Investors should refer to the furnished press release (Exhibit 99.1) for the specific financial figures and guidance, as this 8-K primarily serves to incorporate that information. The report indicates that the company is providing investors with an update on its operational performance and its strategic outlook. While the 8-K itself doesn't contain the numerical results, it directs stakeholders to the comprehensive press release which likely details revenue, profitability, and key growth drivers. The inclusion of 2024 guidance suggests management's confidence or expectations regarding future performance, making it a critical piece of information for valuation and investment decisions.

Zoetis Inc. (ZTS) filed an 8-K on February 6, 2024, primarily to disclose its second quarter 2024 dividend declaration. The company announced a quarterly dividend of $0.432 per share, payable on June 4, 2024, to shareholders of record as of April 19, 2024. This announcement reflects the company's ongoing commitment to returning capital to shareholders. While this filing is limited in scope and does not contain comprehensive financial updates or material business developments, the dividend declaration signals continued confidence from management in the company's financial health and its ability to generate consistent cash flows. Investors focused on income generation and capital return policies will find this information pertinent.

Zoetis Inc. (ZTS) filed an 8-K on December 7, 2023, primarily announcing its first-quarter 2024 dividend. The company declared a dividend of $0.432 per share, payable on March 1, 2024, to shareholders of record as of January 19, 2024. This action signals continued confidence in the company's financial health and its commitment to returning value to shareholders.

Zoetis Inc. (ZTS) has filed a Current Report on Form 8-K on November 2, 2023, to announce its third quarter 2023 financial results and to provide an updated outlook for the full fiscal year 2023. The report primarily consists of a press release detailing these financial outcomes and forward-looking guidance. Investors should pay close attention to the updated full-year guidance as it offers insights into management's expectations for revenue and profitability in the remainder of 2023, reflecting current market conditions and the company's performance trajectory. While the 8-K itself is a notification of the press release, the press release (Exhibit 99.1) contains the core financial details. Investors are encouraged to review this press release for specific figures on revenue, earnings per share, and any segment-specific performance, as well as the updated guidance, which will be critical for assessing the company's strategic execution and potential stock performance in the near term.

Zoetis Inc. reported strong third-quarter results for 2023, with total revenue increasing by 7% to $2.15 billion, driven by an 8% operational increase. This growth was primarily fueled by price increases (approximately 5%) and volume growth from new products and key dermatology products. Net income attributable to Zoetis Inc. rose by 13% to $596 million, with diluted EPS increasing to $1.29 from $1.13 in the prior year period. The company demonstrated robust performance across both its U.S. and International segments, with companion animal products showing significant strength, particularly driven by their key dermatology portfolio and monoclonal antibody (mAb) products like Solensia and Librela. The company also highlighted a healthy increase in operating cash flow for the first nine months of 2023, reaching $1.46 billion, indicating strong cash generation. Strategic acquisitions, such as PetMedix and adivo, are being integrated, and the company continues to invest in research and development to support future innovation. Despite some headwinds from foreign exchange impacts and increased interest expenses, Zoetis maintains a solid financial position, supported by a well-managed debt structure and ample liquidity from its credit facilities.

Zoetis Inc. (ZTS) announced on October 12, 2023, that its Board of Directors has declared a quarterly dividend of $0.375 per share for the fourth quarter of 2023. This dividend underscores the company's commitment to returning capital to shareholders and reflects its ongoing financial stability and confidence in its business outlook. The dividend is scheduled to be paid on December 1, 2023, to shareholders of record as of the close of business on November 1, 2023. While this filing primarily relates to the dividend declaration, it also serves as a reminder of Zoetis's consistent dividend policy, which is a key consideration for income-focused investors.

Zoetis Inc. (ZTS) has filed an 8-K report on August 8, 2023, to announce its financial results for the second quarter of 2023 and provide an update to its full-year 2023 guidance. The key takeaway for investors is the company's performance in Q2 and its revised outlook for the remainder of the year, which are detailed in the accompanying press release furnished as an exhibit. Investors should review this press release for specific financial metrics, including revenue, earnings, and any changes to strategic priorities or operational performance that may have influenced the updated guidance. While the 8-K itself is a procedural filing, the furnished press release contains the substantive information regarding Zoetis' financial health and future expectations. This includes details on how the company is performing against its targets and what factors are driving the updated full-year outlook. Understanding these elements is crucial for assessing the company's trajectory and making informed investment decisions.

Zoetis Inc. (ZTS) reported strong financial results for the period ending June 30, 2023. The company demonstrated robust revenue growth, driven by both price increases and volume growth across its product lines, particularly in companion animal offerings and new product introductions. Despite some foreign exchange headwinds, operational performance remained solid, showcasing the company's resilience and effective market strategies. Profitability saw a significant increase, with net income attributable to Zoetis Inc. rising notably. This improvement was supported by favorable cost management, including a reduction in the cost of sales as a percentage of revenue due to favorable foreign exchange, price increases, and improved product mix. While operating expenses like SG&A and R&D saw planned increases to support innovation and growth, they were managed effectively relative to revenue growth. The company's strategic investments in R&D and operational enhancements continue to position Zoetis for sustained long-term growth in the global animal health market.

Zoetis Inc. (ZTS) filed an 8-K on May 25, 2023, primarily to furnish materials related to its upcoming Investor Day event scheduled for the same date. This filing includes a press release and the presentation materials that will be used by the executive management team. Investors should view this 8-K as a notification and a conduit for accessing important forward-looking information and strategic updates that will be shared during the Investor Day event. While this 8-K does not contain new financial results or material operational changes, it signifies an opportunity for investors to gain deeper insights into Zoetis's strategy, growth drivers, and outlook directly from its leadership. The furnished documents are expected to provide details on the company's performance, pipeline, and future plans within the animal health sector. Investors are encouraged to review Exhibits 99.1 and 99.2 for a comprehensive understanding of the information presented.

Zoetis Inc. held its 2023 Annual Meeting of Shareholders on May 18, 2023, where significant amendments to its governance structure were approved by shareholders. The most impactful change is the shareholder approval of an amendment to the Restated Certificate of Incorporation to allow for the calling of special meetings. This move, along with corresponding by-law amendments, grants shareholders more direct influence on the company's governance by providing a mechanism to convene special meetings under defined conditions. The company also saw overwhelming support for the election of its eight director nominees and the ratification of its independent auditor, KPMG LLP. Furthermore, the shareholders approved the company's executive compensation program on an advisory basis, indicating general satisfaction with the current remuneration structure. The adoption of the special meeting right, following specific procedures and limitations outlined in the amended by-laws, signifies a step towards enhanced shareholder engagement and corporate governance. Investors should monitor how these new provisions are utilized and the potential impact on future strategic decisions and shareholder activism.

Zoetis Inc. (ZTS) filed an 8-K on May 11, 2023, primarily to announce its third-quarter 2023 dividend declaration. The company has declared a cash dividend of $0.375 per share, representing a continued commitment to returning capital to shareholders. This dividend is scheduled to be paid on September 1, 2023, to shareholders of record as of July 21, 2023. While this filing is limited in scope, the dividend declaration signals ongoing financial health and confidence in future performance, which is a positive signal for investors focused on income and stability.

Zoetis Inc. reported $2.00 billion in revenue for the first quarter of 2023, a slight increase of 1% year-over-year, or 4% on an operational basis, excluding foreign exchange impacts. While the company experienced overall revenue growth driven by price increases and new product volume, a slight decrease in overall net income attributable to Zoetis Inc. to $552 million from $595 million in the prior year was observed. This decline was influenced by increased cost of sales, selling, general, and administrative expenses, and research and development spending. Despite the dip in net income, the company's operational performance remains robust, with positive revenue growth and substantial operating cash flow generation of $549 million. The balance sheet shows a healthy liquidity position with $2.1 billion in cash and cash equivalents. Zoetis also continues its commitment to shareholder returns through dividends and share repurchases, with $2.3 billion remaining on its authorized repurchase program.